Husker, I am happy to see you are still interested in our products. My offer to provide you with a coupon is still on the table.
In terms of how we developed the 'equivalency' that is provided on our sales pages as well as our white papers, it is not that difficult to understand. The idea was to look at the totality of hormonal activity that occurs when a user administers testosterone, and compare that activity in terms of what we know about the administration of the DHEA products found in the androseries. This allows us to provide a comparison to the end user that gives a general idea of product expectations, and allows a comparison to be made between these hormones and testosterone (Users who have previously claimed that you can/should not compare hormones to Testosterone must forget that the comparison is the basis for Vida's Androgens and Anabolic Agents, the same book that most the 'internet gurus' will be quick to note in their own arguments).
In order to determine an appropriate comparison for the Androseries products to testosterone, Eric analyzed newer in-vivo and in-vitro studies concerning androgen receptor binding and what we know concerning various base information on anabolic agents found in Vida's Hersheberger assay/in-vivo studies on rats. The next step was to determine what rate of absorption can be expected in regards to these hormones, the addition of their respective esters and the inhibition of enzymes provided by our new liquavade carrier. There are many studies (I believe nearly 160 provided for AndroMass) available in our white pages that will demonstrate the various studies that were utilized int he calculation of these expected values. One we had a reasonable idea of how the absorption would be, we were able to compare that to what has been demonstrated in studies in terms of hormonal activity (Bio-assay/Vida), and come to the conclusion of what can be expected from these products.
In terms of you condescending comments regarding our usage of A:A:E ratios, these ratios were provided on the basis of what has been demonstrated in bio assay studies and Vida, and allowed us to formulate a hybrid equivalence claim. In terms of the importance of estrogen in the matter, you seem to be concentrating the most extreme portion of the equivalence, in which there is relatively (in comparison to testosterone/DHT/etc), less weight in regards to this equivalency. There is a heavily growing movement in endocrinology to look at a TRT patient in terms of total hormonal activity, and not just of testosterone, and this is within good reason. There is overlap in activity between these hormones that makes an understanding of the 'big picture' of androgenic/hormonal activity more relevant than merely measuring just the individual hormones.
Although I find your knowledge on hormones to be rather weak, given posts you have made that I have had the pleasure of reading, and believe this thread was a weak attempt at a call out, I am more than happy to point you in the direction of our white pages an online copies of Vida's text. If you are interested, please send me a PM. I am always happy to talk to you Husker.
Wishing you the best at all times,
-HTS